Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel

Naama Hermann*, Pnina Mor, Orit Kaidar-Person, Rinat Bernstein-Molho, Mali Brodsky, Dana Madorsky Feldman, Anath A. Flugelman, Hadar Aboody Nevo, Danna Meshoulam Avital, Miri Sklair-Levy, Eitan Friedman, Tanir M. Allweis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Population screening for the BRCA mutations in Ashkenazi Jewish women was recently implemented in Israel and is expected to lead to a 10-fold increase in the diagnosis of asymptomatic carriers. Performing the screening follow-up within multidisciplinary dedicated clinics for carriers is recommended for early detection and risk reduction. Objectives: To determine the availability, capacity, and practices of dedicated screening clinic for BRCA carriers in Israel. Methods: A telephone-based survey of all public hospitals in Israel was conducted October 2020 to August 2021 to determine whether they had a dedicated clinic. Dedicated clinics were defined as multidisciplinary screening clinics offering at least breast and gynecological screening and risk reducing services on site. The clinic director or nurse navigator answered a questionnaire about screening practices followed by a semi-structured interview. Results: Of the ten dedicated BRCA clinics found in Israel, nine participated. Approximately 4500 BRCA carriers are currently being followed. No specialized clinics are available in the southern district or in the northernmost half of the northern district of Israel, leading to a disparity between periphery and center. Screening recommendations, although asserted as adhering to international guidelines, vary among clinics including age at initiating of clinical exam, use of adjunct imaging modalities, and follow-up during lactation and after risk reducing surgery. Conclusions: There is a suboptimal distribution of dedicated clinics for BRCA carriers in Israel. Nationally centralized attempt to create guidelines that will unify screening practices is warranted, especially considering the expected increase in demand.

Original languageAmerican English
Pages (from-to)18-22
Number of pages5
JournalIsrael Medical Association Journal
Issue number1
StatePublished - Jan 2023

Bibliographical note

Publisher Copyright:
© 2023 Israel Medical Association. All rights reserved.


  • BRCA
  • Hereditary Breast and Ovarian Cancer Syndrome
  • breast neoplasms/genetics
  • risk management


Dive into the research topics of 'Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel'. Together they form a unique fingerprint.

Cite this